Rosacea: Practical Guidance and Challenges for Clinical Management
Cassidy Nguyen,Guilherme Kuceki,Michael Birdsall,Dev Ram Sahni,Vikram Sahni,Christopher M Hull
DOI: https://doi.org/10.2147/ccid.s391705
2024-01-24
Clinical Cosmetic and Investigational Dermatology
Abstract:Cassidy Nguyen, 1, &ast Guilherme Kuceki, 1, &ast Michael Birdsall, 1 Dev Ram Sahni, 2, 3 Vikram Nath Sahni, 2 Christopher M Hull 2 1 School of Medicine, University of Utah, Salt Lake City, UT, USA; 2 Department of Dermatology, University of Utah Health, Salt Lake City, UT, USA; 3 Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA &astThese authors contributed equally to this work Correspondence: Dev Ram Sahni, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA, 02115, USA, Tel +16177324918, Email Rosacea is a common chronic dermatosis. Clinically, rosacea can present with flushing, erythema, papules, pustules, telangiectasias, phymatous changes, pruritus, burning, and stinging. In 2017, the National Rosacea Society Expert Committee recommended a phenotype-based classification for therapy. In this review, we identify monotherapies and multimodal treatment approaches for the clinical management of rosacea including topical, systemic, laser and light, alternative, and combination therapies. Keywords: combination therapy, management, monotherapy, rosacea, therapy, treatment Rosacea is a common chronic dermatosis with a prevalence of approximately 5.46% of the global population. 1 However, prevalence is theoretically higher as these percentages do not account for patients with milder, unrecognized disease. The first reported account of rosacea was in the 14th century by Dr Guy de Chauliac, a French surgeon, who described "red lesions on the face" and termed the condition "goutterose"—French for "pink droplet"—or "couperose", which remains as a term still used in French medical language. 1 Onset of illness commonly emerges in middle to late adulthood and affects males and females equally, with a predominance of disease occurring in Northern European populations. 2 Rosacea clinically presents with centrofacial erythema, prominent blood vessels, papules, and pustules. 3 In 2002, the National Rosacea Society Expert Committee developed a subtype-based standardized classification system. 4 The proportions of those affected by rosacea were found to be 56.7% (95% CI, 51.4–62.0%) for erythematotelangiectatic rosacea (ETR), 43.2% (95% CI, 38.8–47.6%) for the papulopustular subtype (PPR), 7.4% (95% CI, 6.1–8.9%) the phymatous subtype, and 11.1% (95% CI, 6.7–16.3%) the ocular subtype. 5 These subjective subtype designations made it difficult to categorize patients considering the overlap of symptoms between categories. Over the next 15 years, further insights into the pathogenesis and pathophysiology of rosacea led to the 2017 updated classification guidelines that provided a phenotype-based approach that aimed to describe more explicit parameters based on clinical presentation and their respective, diagnostic positive predictive values. 6 Instead of subtyping, the new classification system groups pathognomonic centrofacial erythema with major phenotypic criteria—papules, pustules, flushing, telangiectasia, and ocular involvement. Secondary phenotypes include burning, stinging, edema, and dry appearance. 6 These new guidelines facilitate the individualization and customization of treatment for each patient. The pathophysiology of rosacea is not entirely understood, but a multifactorial component is suspected with both genetic and environmental factors contributing to its development and progression. 7 Mechanisms of disease propagation include both contribution from innate and adaptive immunity. Inflammation may be caused by dysregulation of proinflammatory cytokines (eg, IL-1, IL-3, and IL-8), alteration and dilation of small blood vessels, imbalances in the skin's microbiome, genetic factors, and environmental triggers. 1,7,8 There remains a lack of consensus on whether varying subtypes of rosacea are individualized clinical entities or if they represent a spectrum of disease progression. However, emerging studies have revealed that the diverse features of this disease and its numerous phenotypes may be part of a range of inflammation that is detectable both histologically and biochemically. 9–12 UV light induces the production of vitamin D, which promotes cathelicidin expression in keratinocytes. Biochemically, patients with rosacea exhibit aberrant expression of cathelicidin, kallikrein-related peptidase 5 (KLK5), and subsequent cleaved product LL-37. The aberrantly cleaved LL-37 leads to disruption in regulation of leukocyte chemotaxis, angiogenesis (facilitated by CXCR chemokine receptor-ligands), expression of extracellular matrix components, and activation of NF-κB, which clinically correlate with the characteristic facial erythema -Abstract Truncated-
dermatology